Vaccine Adjuvants Market Share

North American Market Forecast

The market share of vaccine adjuvants in North America, amongst the market in all the other regions, is projected to be the largest with a share of about 35% by the end of 2037. The growth of the vaccine adjuvants market can be attributed majorly to the large population of elderly individuals and the increasing prevalence of chronic diseases, such as cancer, diabetes, and heart disease. Vaccine adjuvants enhance the immune system's response to the vaccine, resulting in a stronger and more effective response. With high recommendations for children’s vaccines, the demand for vaccine adjuvants in North America is expected to increase. For instance, United States standard recommendations include 10 vaccines for children between the ages of birth and 10 including hepatitis A (HepA); hepatitis B (HepB); RV; diphtheria, tetanus, and others. Additionally, increasing awareness about the importance of vaccinations, advances in vaccine technologies such as mRNA, and the growing adoption of preventive healthcare measures are likely to drive the growth of the market in this region. mRNA vaccines have revolutionized the speed of development and deployment of vaccines. mRNA vaccines are based on messenger RNA which provides instructions to cells to produce proteins that stimulate an immune response. These factors are anticipated to boost the vaccine adjuvants market growth during the forecast period.

APAC Market Statistics

The Asia Pacific vaccine adjuvants market is estimated to be the second largest, registering a share of about 24% by the end of 2037. The growth of the market can be attributed majorly to the increased investment in vaccine research and development as well as the growing demand for combined vaccines. It was observed that a total of over USD 1 billion has been invested in Chinese vaccine research and development. A further 11.35 million doses of Covishield were exported by India in the year 2021. These doses were sent to 92 countries, including health workers and peacekeepers from the UN. Additionally, the rising prevalence of lifestyle-related diseases such as cancer and diabetes, as well as high prevalence of infectious diseases such as malaria and dengue, are expected to drive the demand for vaccines in the region, thus driving the growth of the vaccine adjuvant market in the Asia Pacific region.

Europe Market Forecast

Further, the vaccine adjuvants market in the Europe, amongst the market in all the other regions, is projected to hold a majority of the share by the end of 2037. The growth of the market can be attributed majorly to the presence of a large number of vaccine manufacturers in the region and the increasing government support for vaccination programs. Additionally, Europe is also witnessing an increase in the prevalence of chronic diseases resulting in an increase in vaccine demand. Vaccines work by introducing a weakened or inactive form of a virus or bacteria into the body, prompting the immune system to produce antibodies and build immunity. Adjuvants are added to vaccines to enhance the body’s immune response and to reduce the amount of the active ingredient, or antigen, needed in a vaccine. This makes them more effective at combating chronic diseases and are anticipated to boost the vaccine adjuvants market growth during the forecast period.